NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022)

CompletedPhase 1

Sponsor: Merck Sharp & Dohme LLC

Conditions: Healthy

Interventions: Nemtabrutinib, Diltiazem

Countries: United States

The goal of the study is to learn what happens to levels of nemtabrutinib (MK-1026) in a healthy person's body over time. Researchers will compare what happens to nemtabrutinib in the body when it is given with or without another medicine called diltiazem.

Eligibility overview

Sex: ALL

Age: 18 Years to 55 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Be in good health
* BMI between 18.5 and 32 kg/m2, inclusive

Exclusion Criteria:

* History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological (history of a bleeding disorder, abnormal bleeding or a hereditary or acquired coagulation or platelet disorder), hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke, intercranial hemorrhage, and chronic seizures) abnormalities or diseases
* History of cancer (malignancy)

Locations (1)

Madison, Wisconsin, United States